ABSTRACT
INTRODUCTION: Teleconsultation is an emerging tool whose utilization dramatically increased during the Covid-19 pandemic. Our aim was to determine its clinical accuracy. METHODS: This prospective study was carried out during the first wave of Covid-19. Patients were teleconsulted by either general practitioners or emergency doctors reporting clinical exam results to the ID physicians by phone. Five signs were specifically checked: dyspnea, fever, cough, anosmia and flu-like illness. Data collected by remote consultation were compared to face-to-face examination in an ID Department. RESULTS: From March to April 2020, 149 patients were seen by remote medical care. Dyspnea was found in 14.1% of the teleconsultation patients vs 3.4% in face-to-face consultation; fever in 47.0 vs. 15.4%; cough in 69.1 vs. 16.1%; anosmia in 3.4 vs. 1.3%; flu-like illness in 53.0 vs. 7.4% (all differences significant: P<0.001). CONCLUSION: We observed incongruency between remote and face-to-face consultation for the main clinical signs of Covid-19.
Subject(s)
COVID-19 , Remote Consultation , Anosmia , COVID-19/epidemiology , Cough , Dyspnea , Family Practice , Fever , Humans , Pandemics , Prospective Studies , Remote Consultation/methods , SARS-CoV-2ABSTRACT
INTRODUCTION: Our aim was to determine the rate of success of HFNO and its relationship with current treatments for severe COVID-19. METHOD: This was a cohort study including patients admitted for HFNO because of respiratory failure despite oxygen therapy through a facial mask. Care was standardized, with systematic use of steroids and prevention or treatment of thromboembolic complications, and tocilizumab when deemed useful. HFNO failure was defined by the requirement for mechanical ventilation and/or death. RESULTS: In August 2021, among 1397 patients with COVID-19 admitted in the emergency department, 110 (7.8%) received HFNO (mean age 55 years, sex-ratio M/F 1.4). Thirteen patients (12%) had received a steroid treatment before hospital admission. At least one comorbid condition was observed in 57% of the patients. Mean duration of the disease at admission was 8.8 days and mean respiratory rate was 34/min. A CT scan was performed for 101 patients (92%), among whom 13 had a pulmonary embolism. All patients received a steroid treatment, and tocilizumab was prescribed in 79 cases (72%). Failure of HFNO was observed in 54 cases (49%); the only risk factor was the absence of tocilizumab administration: AOR [IC95%] 3.50 [1.40-8.69]. We observed a trend toward failure with steroid use before hospital admission: AOR 3.83 [0.96-16.66]. CONCLUSION: Success of HFNO, when all therapeutic means of treatment for severe COVID-19 pneumonia were applied, was associated with tocilizumab administration. Our data suggest the interest of a randomized study to determine whether HFNO is the right signal for prescription of anti-IL6 drugs.
Subject(s)
COVID-19 Drug Treatment , COVID-19 , Antibodies, Monoclonal, Humanized , COVID-19/therapy , Cannula , Cohort Studies , Humans , Middle AgedABSTRACT
OBJECTIVE: The Covid-19 pandemic is the major global health crisis of our time. The purpose of this study is to estimate the seroprevalence of IgG against SARS-CoV-2 among workers in the University Hospi-tal of Guadeloupe and to assess this seroprevalence in asymptomatic personnel as well as the proportion of asymptomatic agents among seropositive agents. SETTING AND METHODS: We carried out a seroprevalence study in the staff of the University Hospital of Guadeloupe. The presence of IgG anti SARS-CoV-2 was determined by a micro-particulate immunolo-gical assay using the chemiluminescence technique (CMIA, Architect i2000SR, Abbott). Data on the previous presence of symptoms sugge-stive of COVID-19, were identified using a standardized questionnaire. Statistical analyses were performed using Epi Info® software. RESULTS: From 07/05/2020 to 28/10/2020, 892 serologies were performed, 45 of which were positive for SARS-CoV-2 : a prevalence of 5.0% [95% CI: 3.6% - 6.5%]. Seroprevalence was 1.5% [95% CI: 0.6% - 2.3%] among agents who reported being asymptomatic. Among seropositive individuals, 24.4% [95% CI:12% - 36%] was totally asymptomatic. CONCLUSION: Our results highlight the importance of continuing seroprevalence studies for SARS-CoV-2 in hospital staff, which can provide important information on the level of exposure in healthcare workers and asymptomatic transmission of SARS-CoV-2 in clinical set-tings.
Subject(s)
COVID-19 , SARS-CoV-2 , Guadeloupe , Hospitals , Humans , Immunoglobulin G , Pandemics , Seroepidemiologic StudiesABSTRACT
BACKGROUND: For several years, we applied an internal guideline for community-acquired urinary tract infections (cUTI), targeting the reduction of fluoroquinolone use (FQ) and thereby favouring cotrimoxazole (CTM) prescription. Our aim was to report adverse effects (AE) and outcome for patients presenting with cUTI and treated with these compounds. METHODS: This cohort study was based on the dashboard of our department, bringing together 28 parameters for all patients, including diagnosis, microbiological data, antibiotic therapy, AE, length of hospital stay (LHS) and outcome. We included all patients with cUTI due to Enterobacteriaeae treated with CTM or FQ, and compared these 2 groups on in-hospital AE, LHS, and unfavourable outcome defined as intensive care requirement or death. RESULTS: From June 2008 to June 2019, 640 cUTI due to Enterobacteriaeae were observed, among which 295 (46%) treated with CTM and 345 (54%) with a FQ. There were 25 AE (3.9%): 17 (5.7%) in the CTM group, and 8 (2.3%) in the FQ group (P=0.025). Adverse effects were associated with increased LHS compared to patients without AE: 11±6 vs. 7±4 days respectively, P<0.001, 11.4±6.2 days in the CTM group vs. 9.2±5.8 in the FQ group (relative LHS increase of 73.5% and 29.5%, respectively). Unfavorable outcome occurred for 1 patient (0.3%) in the CTM group, and 5 (1.4%) in the FQ group, P=0.297. CONCLUSION: Favouring cotrimoxazole for cUTI due to Enterobacteriaceae was associated compared to FQ with more AE and prolonged LHS. A cost-effectiveness analysis to validate such therapeutic strategy is warranted.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Fluoroquinolones/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Urinary Tract Infections/drug therapy , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Cohort Studies , Community-Acquired Infections/drug therapy , Community-Acquired Infections/mortality , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/mortality , Female , Fluoroquinolones/adverse effects , Humans , Intensive Care Units/statistics & numerical data , Length of Stay/statistics & numerical data , Male , Middle Aged , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Urinary Tract Infections/mortalityABSTRACT
OBJECTIVES: We reported the impact of internal guidelines coupled with selective reporting of antibiotic susceptibility tests (srAST) on antibiotic adequacy in healthcare facilities. METHODS: This prospective study involved clinicians from three clinics with medical and surgical activities employing a full-time infectious disease (ID) specialist. Internal guidelines were updated in 2016. The clinics were working with the same laboratory, which delivered the srAST introduced in March 2017. Two weeks per month over a 6-month period, all isolated bacterial specimens, empirical antibiotic therapies (EAT) and the documented ones were analyzed. An EAT listed in the guidelines and a documented therapy mentioned in the srAST defined their adequacy. RESULTS: A total of 257 positive bacterial samples were analyzed in 199 patients, for which 106 infections were studied. Of these, 32% were urinary tract infections, 15% were primary bloodstream infections, 11% were bone infections, and 42% were other types of infection. The three main bacteria were Escherichia coli (27%), Staphylococcus aureus (24%), and Enterococcus faecalis (14%). The total number of antibiotic prescriptions was 168, with 75 (45%) EATs and 93 (55%) documented therapies. There were 35/75 (47%) adequate EATs and 86/93 (92%) adequate documented therapies. The ID specialist was not involved in 90/168 (53.5%) prescriptions, of which 43/90 (48%) were adequate, with 21/35 (60%) EATs and 22/86 (25%) documented therapies. There was a statistical correlation between compliance of the EATs with guidelines and of the documented therapy with srAST (p=0.02). CONCLUSION: Combining internal guidelines and srAST led to a high rate of antibiotic adequacy.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Infections/drug therapy , Microbial Sensitivity Tests/standards , Practice Guidelines as Topic , Aged , Aged, 80 and over , Antimicrobial Stewardship/methods , Bacteremia/drug therapy , Bone Diseases, Infectious/drug therapy , Escherichia coli/isolation & purification , Escherichia coli Infections/drug therapy , Female , France , Health Facilities , Humans , Male , Microbial Sensitivity Tests/methods , Middle Aged , Prospective Studies , Staphylococcal Infections/drug therapy , Staphylococcus aureus/isolation & purification , Urinary Tract Infections/drug therapySubject(s)
Immune Reconstitution Inflammatory Syndrome/diagnosis , Panniculitis/diagnosis , Whipple Disease/complications , Biopsy/methods , Doxycycline/therapeutic use , Glucocorticoids/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/etiology , Male , Middle Aged , Panniculitis/drug therapy , Panniculitis/etiology , Prednisone/therapeutic use , Skin/pathology , Treatment Outcome , Tropheryma/isolation & purification , Whipple Disease/drug therapySubject(s)
Betacoronavirus , Coronavirus Infections/complications , Meningoencephalitis/etiology , Pneumonia, Viral/complications , Acute Disease , Aged , Anti-Bacterial Agents/therapeutic use , Antimalarials/therapeutic use , Azithromycin/therapeutic use , COVID-19 , Coronavirus Infections/drug therapy , Drug Therapy, Combination , Humans , Hydroxychloroquine/therapeutic use , Male , Pandemics , Pneumonia, Viral/drug therapy , SARS-CoV-2Subject(s)
Anti-Bacterial Agents/therapeutic use , Antimicrobial Stewardship/standards , Practice Guidelines as Topic , Anesthesiology/methods , Anesthesiology/organization & administration , Anesthesiology/standards , Antimicrobial Stewardship/methods , Critical Care/methods , Critical Care/organization & administration , Critical Care/standards , France/epidemiology , Humans , Hygiene/standards , Infectious Disease Medicine/methods , Infectious Disease Medicine/organization & administration , Infectious Disease Medicine/standards , Practice Patterns, Physicians'/standards , Practice Patterns, Physicians'/statistics & numerical data , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/epidemiology , Societies, Medical/organization & administration , Societies, Medical/standards , Treatment OutcomeSubject(s)
Aggregatibacter actinomycetemcomitans/isolation & purification , Brain Abscess/microbiology , Gram-Positive Bacterial Infections/microbiology , Methanobrevibacter/isolation & purification , Pasteurellaceae Infections/microbiology , Adult , Aggregatibacter actinomycetemcomitans/genetics , Community-Acquired Infections/microbiology , DNA Restriction Enzymes/genetics , Female , Gram-Positive Bacterial Infections/diagnosis , Humans , Methane/analysis , Methane/biosynthesis , Methanobrevibacter/genetics , Pasteurellaceae Infections/diagnosis , Prospective StudiesABSTRACT
Clindamycin has high bioavailability together with good diffusion in bone tissue and could represent an alternative antibiotic compound for the treatment of bone and joint infections (BJIs). However, data regarding the efficacy and safety of clindamycin for BJIs are limited. A monocentric cohort study based on our medical dashboard, which prospectively recorded 28 characteristics for all hospitalized patients since July 2005, was performed. BJIs were selected, and then, all mono-microbial BJI managed with clindamycin-based therapy were included. Remission was defined as the absence of clinical and/or microbiological relapse after treatment. The duration of follow-up without relapse was determined retrospectively using computerized medical records. For 10 years, 196 BJIs, of which 80 (41%) were device-associated infections, were treated with clindamycin-based therapy. The bacterial causative agent was Staphylococcus aureus in 130 cases (66%), coagulase-negative staphylococci in 29 cases (15%), streptococci in 31 cases (16%) and other bacteria in 6 cases (3%). When used in combination therapy, clindamycin was mainly paired with fluoroquinolones (31%) or rifampin (27%). The mean duration of clindamycin treatment was 7.4 ± 3.2 weeks (range, 1-24). An AE was recorded for 9 (4.5%) patients. Remission was recorded for 111 (57%) patients, with a mean duration of clinical follow-up of 28 ± 24 months. Treatment failure occurred in 22 (11%) patients, 50 patients (25%) were lost to follow-up, and 8 (4%) required long-term suppressive therapy. Among the assessable patients, clindamycin-based therapy was efficient in 111/133 cases (83%) and thus represents a reliable and safe alternative treatment option.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/drug therapy , Clindamycin/therapeutic use , Osteitis/drug therapy , Aged , Aged, 80 and over , Algorithms , Arthritis, Infectious/diagnosis , Arthritis, Infectious/microbiology , Cohort Studies , Comorbidity , Disease Management , Female , Humans , Male , Middle Aged , Osteitis/diagnosis , Osteitis/microbiology , Treatment OutcomeABSTRACT
Infectious diseases are unpredictable, with heterogeneous clinical presentations, diverse pathogens, and various susceptibility rates to anti-infective agents. These features lead to a wide variety of clinical practices, which in turn strongly limits their evaluation. We have been using a medical table since 2005 to monitor the medical activity in our department. The observation of heterogeneous therapeutic practices led to drafting up our own antibiotic guidelines and to implementing a continuous evaluation of their observance and impact on morbidity and mortality associated with infectious diseases, including adverse effects of antibiotics, duration of hospital stay, use of intensive care, and deaths. The 10-year analysis of medical practices using the medical table is based on more than 10,000 hospitalizations. It shows simplified antibiotic therapies and a reduction in infection-related morbidity and mortality. The medical table is a major tool for antimicrobial stewardship, leading to constant benefits for patients.
Subject(s)
Antimicrobial Stewardship/standards , Health Policy , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Humans , Practice Guidelines as TopicSubject(s)
Anti-Bacterial Agents/administration & dosage , Hospitalization , Pulmonary Disease, Chronic Obstructive/therapy , Acute Disease , Aged , Disease Progression , Drug Administration Schedule , Drug Resistance, Microbial , Female , France/epidemiology , Guideline Adherence , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/epidemiologySubject(s)
Abscess/microbiology , Bacterial Proteins/genetics , Bacteroides thetaiotaomicron/isolation & purification , Methanobrevibacter/isolation & purification , Muscle, Skeletal/microbiology , Adult , Bacterial Proteins/metabolism , Bacteroides thetaiotaomicron/genetics , Bacteroides thetaiotaomicron/growth & development , Chronic Disease , Humans , Male , Methanobrevibacter/genetics , Methanobrevibacter/growth & development , Muscle, Skeletal/pathology , RNA, Bacterial/isolation & purification , RNA, Ribosomal, 16S/isolation & purificationABSTRACT
BACKGROUND: The use of rapid microbiological tests is supported by antimicrobial stewardship policies. Targeted antibiotic therapy (TAT) for community-acquired pneumonia (CAP) with positive urinary antigen test (UAT) has been associated with a favorable impact on outcome. We aimed to determine the factors associated with TAT prescription. PATIENTS AND METHODS: We conducted a retrospective multicenter study including all patients presenting with CAP and positive UAT for Streptococcus pneumoniae or Legionella pneumophila from January 2010 to December 2013. Patients presenting with aspiration pneumonia, coinfection, and neutropenia were excluded. CAP severity was assessed using the Pneumonia Severity Index (PSI). TAT was defined as the administration of amoxicillin for pneumococcal infection and either macrolides or fluoroquinolones (inactive against S. pneumoniae) for Legionella infection. RESULTS: A total of 861 patients were included, including 687 pneumococcal infections and 174 legionellosis from eight facilities and 37 medical departments. TAT was prescribed to 273 patients (32%). Four factors were found independently associated with a lower rate of TAT: a PSI score≥4 (OR 0.37), Hospital A (OR 0.41), hospitalization in the intensive care unit (OR 0.44), and cardiac comorbidities (OR 0.60). Four other factors were associated with a high rate of TAT: positive blood culture for S. pneumoniae (OR 2.32), Hospitals B (OR 2.34), E (OR 2.68), and H (OR 9.32). CONCLUSION: TAT in CAP with positive UAT was related to the hospitals as well as to patient characteristics.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antigens, Bacterial/urine , Antimicrobial Stewardship , Community-Acquired Infections/epidemiology , Legionella pneumophila/immunology , Legionnaires' Disease/epidemiology , Pneumonia, Pneumococcal/epidemiology , Streptococcus pneumoniae/immunology , Bacteremia/epidemiology , Community-Acquired Infections/diagnosis , Community-Acquired Infections/microbiology , Community-Acquired Infections/urine , Comorbidity , Diagnostic Tests, Routine , Drug Substitution , Drug Therapy, Combination , Hospital Departments , Hospitalization , Humans , Intensive Care Units , Legionnaires' Disease/drug therapy , Legionnaires' Disease/urine , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/urine , Retrospective Studies , Risk FactorsABSTRACT
Daily practice suggests that respiratory signs may be observed in bacteraemic urinary infections (BUI). Our objective was to search for an association between the presence of respiratory symptoms and the bacteraemic nature of urinary tract infections (UTI). A nested case-control study was carried out based on our computerised dashboard from January 2011 to June 2015. Cases were defined as patients with a BUI due to Enterobacteriaceae species, identified in blood and urine cultures. Controls had fever and a positive urinary sample but sterile blood cultures (NBUI) and a final diagnosis of urinary infection. Patients from the BUI group were 1:1 matched to the NBUI group according to four parameters: age, gender, cardiovascular and pulmonary comorbid conditions. Subjects with cognitive impairment limiting clinical accuracy and those with healthcare-associated infections were excluded. We compared systematically recorded respiratory and urinary symptoms between groups: signs on auscultation, dyspnoea, chest pain, cough and sputum, dysuria with burning, pollakiuria, flank or costovertebral angle tenderness and ischuria. One hundred BUI were compared to 100 NBUI, both groups exhibiting a similar rate for all considered comorbid conditions. In the BUI group, 58 % showed at least one respiratory sign vs. 20 % in the NBUI group, p < 0.001, while urinary signs were less frequent: 54 % vs. 71 %, p = 0.013. In the multivariate analysis, BUI was associated with the presence of abnormal pulmonary auscultation [adjusted odds ratio (AOR), 5.91; p < 0.001] and a trend towards less urinary symptoms (AOR, 1.58; p = 0.058). Patients with BUI presented with significantly more respiratory signs, which overshadowed urinary symptoms, compared to those with non-bacteraemic UTI. Such observations impact clinical decision-making.
Subject(s)
Bacteremia/pathology , Enterobacteriaceae Infections/pathology , Respiratory Tract Infections/pathology , Urinary Tract Infections/complications , Urinary Tract Infections/pathology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Male , Middle AgedSubject(s)
Antimicrobial Stewardship/standards , Health Policy , Infectious Disease Medicine , Practice Guidelines as Topic , Certification , France , Humans , Inappropriate Prescribing/prevention & control , Infectious Disease Medicine/trends , Physician's Role , Practice Patterns, Physicians' , Quality ImprovementABSTRACT
BACKGROUND: As CD4/CD8 ratio inversion has been associated with non-AIDS morbidity and mortality, predictors of ratio normalization after cART need to be studied. Here, we aimed to investigate the association of antiretroviral regimens with CD4/CD8 ratio normalization within an observational cohort. METHODS: We selected, from a French cohort at the Nice University Hospital, HIV-1 positive treatment-naive patients who initiated cART between 2000 and 2011 with a CD4/CD8 ratio <1. Association between cART and ratio normalization (>1) in the first year was assessed using multivariate logistic regression models. Specific association with INSTI-containing regimens was examined. RESULTS: 567 patients were included in the analyses; the median CD4/CD8 ratio was 0.36. Respectively, 52.9%, 29.6% and 10.4% initiated a PI-based, NNRTI-based or NRTI-based cART regimens. About 8% of the population started an INSTI-containing regimen. 62 (10.9%) patients achieved a CD4/CD8 ratio ≥1 (N group). cART regimen was not associated with normalization when coded as PI-, NNRTI- or NRTI-based regimen. However, when considering INSTI-containing regimens alone, there was a strong association with normalization [OR, 7.67 (2.54-23.2)]. CONCLUSIONS: Our findings suggest an association between initiation of an INSTI-containing regimen and CD4/CD8 ratio normalization at one year in naïve patients. Should it be confirmed in a larger population, it would be another argument for their use as first-line regimen as it is recommended in the recent update of the "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents".
Subject(s)
Anti-HIV Agents/therapeutic use , Anti-Retroviral Agents/therapeutic use , CD4-CD8 Ratio , HIV Infections/drug therapy , Viral Load/drug effects , Adult , Anti-HIV Agents/pharmacology , Anti-Retroviral Agents/pharmacology , Cohort Studies , Female , HIV Infections/immunology , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
Positive urinary antigen tests (UAT) for pneumococcal infection in community-acquired pneumonia (CAP) may lead to targeted antibiotic therapy. We report an audit aimed at defining the link between mortality and targeted therapy. We conducted a retrospective multicentre audit of patients with severe CAP for whom a UAT was positive for S. pneumoniae. Patients admitted from January 2010 to December 2013 to 8 medical centres (from A to H) were included. Co-morbidities were defined by the specific treatment administered before hospital care, or if the diagnosis was newly established during the hospital stay. We used the Pneumonia Severity Index (PSI) to assess disease severity. Only patients with PSI > 90 were included. Antibiotic treatments and the PSI were extracted from patients' charts. Amoxicillin had to be prescribed as a targeted antibiotic treatment or at the time of antibiotic reassessment. A total of 389 patients were included. The mean (±STD) PSI score was 128 ± 29; 38.9% of the patients had a class 5 PSI score. Intensive care was required for 36.6% of the patients. Amoxicillin was initially prescribed in 47 cases (12.1%) and in 34 cases after reassessment (8.7%). In logistic regression analysis, we found three parameters associated with mortality: being hospitalised in institution D, class 5 PSI score, and metastatic cancer. In contrast, three antibiotic regimens were protective factors, including targeted therapy: OR = 0.09, p < 0.001. In the context of severe CAP with positive UAT for S. pneumoniae, targeted therapy was associated with a reduction in mortality.